OBJECTIVES: Previously, we found that long intergenic non-coding RNA-p21 (lincRNA-p21) inhibited the development of human prostate cancer. However, the underlying molecular mechanisms are poorly understood. Here, we attempted to investigate the downstream targets of lincRNA-p21 in prostate cancer. MATERIALS AND METHODS: Expression of lincRNA-p21 and PKM2 was determined by qRT-PCR and Western blot. Lentivirus expressing shPKM2 or shCtrl was used to explore the role of PKM2 on the enhanced cell proliferation and glycolysis of lincRNA-p21-silenced prostate cancer cells. A xenograft mouse model was performed to investigate the effect of PKM2 suppression, glycolytic or mammalian target of rapamycin (mTOR) inhibitor on the tumorigenic capacity of lincRNA-p21-silenced prostate cancer cells. RESULTS: We revealed that lincRNA-p21 silencing in DU145 and LNCaP cells induced up-regulation of PKM2 and activation of glycolysis, which could be reversed by PKM2 knockdown or rapamycin treatment. We also found that the proliferation and tumorigenesis of lincRNA-p21-silenced prostate cancer cells were significantly inhibited after knocking down PKM2. 3-bromopyruvate (3-Brpa) or rapamycin treatment largely decreased the tumour burden. Importantly, PKM2 expression was inversely correlated with the lincRNA-p21 level and the survival of prostate cancer patients. CONCLUSIONS: We demonstrated that lincRNA-p21 blunted the prostate cancer cell proliferation and tumorigenic capacity through down-regulation of PKM2. Therefore, targeting PKM2 or glycolysis might be a therapeutic strategy in prostate cancer patients with lowly expressed lincRNA-p21.
OBJECTIVES: Previously, we found that long intergenic non-coding RNA-p21 (lincRNA-p21) inhibited the development of human prostate cancer. However, the underlying molecular mechanisms are poorly understood. Here, we attempted to investigate the downstream targets of lincRNA-p21 in prostate cancer. MATERIALS AND METHODS: Expression of lincRNA-p21 and PKM2 was determined by qRT-PCR and Western blot. Lentivirus expressing shPKM2 or shCtrl was used to explore the role of PKM2 on the enhanced cell proliferation and glycolysis of lincRNA-p21-silenced prostate cancer cells. A xenograft mouse model was performed to investigate the effect of PKM2 suppression, glycolytic or mammalian target of rapamycin (mTOR) inhibitor on the tumorigenic capacity of lincRNA-p21-silenced prostate cancer cells. RESULTS: We revealed that lincRNA-p21 silencing in DU145 and LNCaP cells induced up-regulation of PKM2 and activation of glycolysis, which could be reversed by PKM2 knockdown or rapamycin treatment. We also found that the proliferation and tumorigenesis of lincRNA-p21-silenced prostate cancer cells were significantly inhibited after knocking down PKM2. 3-bromopyruvate (3-Brpa) or rapamycin treatment largely decreased the tumour burden. Importantly, PKM2 expression was inversely correlated with the lincRNA-p21 level and the survival of prostate cancerpatients. CONCLUSIONS: We demonstrated that lincRNA-p21blunted the prostate cancer cell proliferation and tumorigenic capacity through down-regulation of PKM2. Therefore, targeting PKM2 or glycolysis might be a therapeutic strategy in prostate cancerpatients with lowly expressed lincRNA-p21.
Authors: Dana E Rathkopf; Emmanuel S Antonarakis; Neal D Shore; Ronald F Tutrone; Joshi J Alumkal; Charles J Ryan; Mansoor Saleh; Ralph J Hauke; Rajesh Bandekar; Edna Chow Maneval; Carla J de Boer; Margaret K Yu; Howard I Scher Journal: Clin Cancer Res Date: 2017-02-17 Impact factor: 12.531
Authors: S Ros; J Flöter; I Kaymak; C Da Costa; A Houddane; S Dubuis; B Griffiths; R Mitter; S Walz; S Blake; A Behrens; K M Brindle; N Zamboni; M H Rider; A Schulze Journal: Oncogene Date: 2017-01-16 Impact factor: 9.867
Authors: Barry S Taylor; Nikolaus Schultz; Haley Hieronymus; Anuradha Gopalan; Yonghong Xiao; Brett S Carver; Vivek K Arora; Poorvi Kaushik; Ethan Cerami; Boris Reva; Yevgeniy Antipin; Nicholas Mitsiades; Thomas Landers; Igor Dolgalev; John E Major; Manda Wilson; Nicholas D Socci; Alex E Lash; Adriana Heguy; James A Eastham; Howard I Scher; Victor E Reuter; Peter T Scardino; Chris Sander; Charles L Sawyers; William L Gerald Journal: Cancer Cell Date: 2010-06-24 Impact factor: 31.743
Authors: Weiwei Yang; Yan Xia; David Hawke; Xinjian Li; Ji Liang; Dongming Xing; Kenneth Aldape; Tony Hunter; W K Alfred Yung; Zhimin Lu Journal: Cell Date: 2012-08-17 Impact factor: 41.582
Authors: Sebastien Rinaldetti; Thomas Stefan Worst; Eugen Rempel; Maximilian C Kriegmair; Arndt Hartmann; Stefan Porubsky; Christian Bolenz; Philipp Erben Journal: Sci Rep Date: 2020-11-24 Impact factor: 4.379
Authors: Marvin C J Lim; Anne-Marie Baird; John Aird; John Greene; Dhruv Kapoor; Steven G Gray; Ray McDermott; Stephen P Finn Journal: Diagnostics (Basel) Date: 2018-08-30